In an effort to make COVID-19 diagnostic testing easier and more readily available to Arizonans, researchers at Arizona State University have developed the state’s first saliva-based test.Continue reading
Author Archive: AZBio
Kalos therapeutics announces important progress in therapeutic peptide for cancer program
Kalos therapeutics is developing a novel, small peptide with activity against human pancreatic cancer
Continue reading
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
- Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone
- Data Add to Body of Evidence from Prior Studies Demonstrating Benefit of Remdesivir in Hospitalized Patients with COVID-19
Lilly Begins World’s First Study of a Potential COVID-19 Antibody Treatment in Humans
“Lilly scientists delivered the first doses of our potential #COVID19 antibody treatment, flown to hospitals in several U.S. cities to start the world’s first human study of this kind of therapy to fight COVID infections.” @lillypad
- First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly’s collaboration with AbCellera
- The placebo-controlled study will assess safety and tolerability in patients hospitalized with COVID-19 with results anticipated by the end of June
- Should Phase 1 results show the antibody can be safely administered, Lilly will initiate a Phase 2 proof of concept study to assess efficacy in vulnerable populationsContinue reading
UArizona Pharmacy Researcher Identifies Compounds That May Lead to Potential Treatments for COVID-19
Findings on compounds that block SARS-COV-2 viral replication may offer a promising starting point for further development of treatments to address the ongoing, devastating novel coronavirus pandemic.Continue reading
Merck to Announce Multiple Scientific Efforts to Combat COVID-19
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate. Today’s announcements are:
- Merck to acquire Themis Bioscience, a company focused on vaccines and immune-modulation therapies for infectious diseases, including COVID-19;
- IAVI and Merck collaborate to develop vaccine against COVID-19;
- Merck and Ridgeback Bio collaborate to advance development of an oral antiviral candidate for COVID-19, EIDD-2801.
Cost-effective cancer vaccine offers promise for prevention and treatment
In a new study appearing in the journal BMC Immunology, lead researcher Milene Peterson along with a team of researchers including Stephen Johnston, all in the Biodesign Center for Innovations in Medicine, took a look at the efficacy of personal vaccines versus shared vaccines, which target mutations shared by the majority of individuals with a cancer subtype.Continue reading
UArizona Names Surgeon General Carmona to Lead Campus Reentry Plan
University of Arizona President Dr. Robert C. Robbins announced in April his plans to resume in-person classes Aug. 24, bringing back 45,000 students and 15,000 faculty and staff for fall 2020.Continue reading
Banner Health experts: Staying safe as COVID-19 restrictions ease
Practiced together, CDC guidelines help to reduce riskContinue reading
Researchers Investigate How COVID-19 Impacts the Brain
The project will leverage an existing online survey tool that researchers have used to investigate risk factors for Alzheimer’s disease.